Profile data is unavailable for this security.
About the company
Sino Biopharmaceutical Limited is an investment holding company principally engaged in the medicine products business. The Company operates through three business segments. The Modernized Chinese Medicine and Chemical Medicine segment is engaged in the manufacture, sale and distribution of modernized Chinese medicine products and western medicine products. The Investment segment is principally engaged in the long term and short term investments. The Other segment is principally engaged in the related medical and hospital business.
- Revenue in HKD (TTM)29.21bn
- Net income in HKD2.18bn
- Incorporated2000
- Employees24.44k
- LocationSino Biopharmaceutical LtdUnit 09, 41F, Office TowerConvention Plaza, No. 1 Harbour RoadWanchai Hong KongHKG
- Phone+852 28029886
- Fax+852 28800847
- Websitehttp://www.sinobiopharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China Resources Pharmaceutical Group Ltd | 273.07bn | 4.11bn | 34.99bn | 72.76k | 8.51 | 0.6639 | 2.78 | 0.1282 | 0.6549 | 0.6549 | 43.47 | 8.39 | 0.966 | 6.09 | 3.28 | 3,741,414.00 | 3.19 | 3.02 | 12.13 | 11.35 | 15.78 | 15.72 | 3.31 | 2.87 | 1.12 | 11.50 | 0.4396 | 24.73 | 12.16 | 8.86 | 10.11 | 2.80 | 13.58 | 7.05 |
| Innovent Biologics Inc | 8.13bn | -1.40bn | 58.06bn | 5.26k | -- | 4.27 | -- | 7.14 | -0.8752 | -0.8752 | 5.07 | 8.32 | 0.3905 | 1.32 | 6.25 | 1,668,124.00 | -6.71 | -13.06 | -8.22 | -15.85 | 82.44 | 84.51 | -17.18 | -43.44 | 2.51 | -6.91 | 0.2123 | -- | 36.21 | 265.79 | 52.83 | -- | 34.60 | -- |
| Sino Biopharmaceutical Ltd | 29.21bn | 2.18bn | 65.96bn | 24.44k | 29.70 | 1.80 | 10.46 | 2.26 | 0.1182 | 0.2419 | 1.58 | 1.95 | 0.4050 | 2.37 | 3.74 | 1,131,731.00 | 7.42 | 13.11 | 14.50 | 21.74 | 82.92 | 80.37 | 18.33 | 27.47 | 1.07 | 18.13 | 0.1868 | 25.02 | 0.6657 | 4.63 | -10.29 | -27.22 | -7.18 | 1.15 |
| CSPC Pharmaceutical Group Ltd | 34.50bn | 6.46bn | 71.23bn | 20.30k | 11.17 | 1.91 | 18.16 | 2.06 | 0.5452 | 0.5452 | 2.91 | 3.19 | 0.6914 | 3.01 | 4.99 | 1,468,053.00 | 13.25 | 16.08 | 17.64 | 21.57 | 71.38 | 72.95 | 19.16 | 19.63 | 2.22 | 40.86 | 0.0106 | 35.51 | 1.66 | 12.16 | -3.58 | 13.77 | -2.58 | 25.33 |
Data as of Nov 01 2024. Currency figures normalised to Sino Biopharmaceutical Ltd's reporting currency: Hong Kong Dollar HKD
8.14%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 02 Oct 2024 | 353.90m | 1.88% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 185.76m | 0.99% |
| Hang Seng Investment Management Ltd.as of 04 Oct 2024 | 162.05m | 0.86% |
| GF Fund Management Co., Ltd.as of 30 Jun 2024 | 139.45m | 0.74% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 127.47m | 0.68% |
| Zhong Ou Asset Management Co., Ltdas of 30 Jun 2024 | 126.44m | 0.67% |
| Aegon-Industrial Fund Management Co., Ltd.as of 30 Jun 2024 | 119.96m | 0.64% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 116.51m | 0.62% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 106.26m | 0.57% |
| HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 2024 | 91.49m | 0.49% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
